We need data to see the efficacy of Novo Nordisk's weight-loss drug, Fresenius CEO says
Michael Sen, CEO of healthcare provider Fresenius, discusses third-quarter earnings and the impact of rival Novo Nordisk's weight-loss drug Wegovy on its dialysis business.
Видео We need data to see the efficacy of Novo Nordisk's weight-loss drug, Fresenius CEO says канала CNBC International TV
Видео We need data to see the efficacy of Novo Nordisk's weight-loss drug, Fresenius CEO says канала CNBC International TV
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Kering shares dive after first-half profit warning
KRBL discusses its strategy as share of agriculture in India's GDP declines
One interest rate cut in 2024 'looks quite reasonable,' strategist says
Airbus CFO says first-quarter earnings ‘not particularly strong’ but reaffirms full-year guidance
Singapore banks look 'fantastic,' says analyst
Company focus will be on Saudi Arabia, DAMAC chairman says
HK spot crypto ETF market has the potential to be double the size of the U.S.: CEO
Nio CEO: We want to keep prices of our cars stable
Telenor CEO: AI is not new to us
IMF chief concerned about the prospect of central banks diverging on rate cuts
Saudi Arabia’s focus is on non-oil growth is strong: Economy minister
More risks buying spot crypto ETFs with cash than in-kind purchases: HashKey
AstraZeneca tops first-quarter revenue and profit expectations
Invesco: Expect one to two Fed rate cuts this year
Parts of the European market look very attractive for AI plays, fund manager says
Japanese yen is a 'huge buying opportunity' at these levels, says investment advisory firm
FatHopes Energy on what could stir sustainable aviation fuel demand
Supply security is top priority amid the energy transition: Strategist
We can easily see the Bank of Japan moving in June: State Street Global Markets
U.S. and UK experiencing different types of inflation, investor says
Samsung's memory business will get a lift when AI PCs hit the shelves, advisory firm says